Literature DB >> 16281942

Haploinsufficiency of Runx1/AML1 promotes myeloid features and leukaemogenesis in BXH2 mice.

Namiko Yamashita1, Motomi Osato, Liqun Huang, Masatoshi Yanagida, Scott C Kogan, Masayuki Iwasaki, Takuro Nakamura, Katsuya Shigesada, Norio Asou, Yoshiaki Ito.   

Abstract

Haploinsufficiency of RUNX1/AML1 is associated with familial platelet disorder with a predisposition to acute myeloid leukaemia (FPD/AML), but the causal relationship remains to be addressed experimentally. Mice heterozygous for the Runx1 null mutation, Runx1+/-, are considered to be genetically comparable with human FPD/AML patients but do not develop spontaneous leukaemia. To induce additional genetic alterations, retroviral insertional mutagenesis was employed with the use of BXH2 mice, which develop myeloid leukaemia because of the random integration of retrovirus present in the mouse. Heterozygous disruption of Runx1 in BXH2 mice resulted in a shortening of the latency period of leukaemia. In addition, BXH2-Runx1+/- mice exhibited more marked myeloid features than control mice. Moreover, the c-Kit gene, mutated in human RUNX leukaemias, was recurrently activated in BXH2-Runx1+/- mice, and a colony-forming assay revealed synergism between the Runx1+/- status and c-KIT overexpression. In conclusion, the BXH2-Runx1+/- system is a promising mouse model to investigate the mechanism of leukaemogenesis in FPD/AML.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16281942     DOI: 10.1111/j.1365-2141.2005.05793.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

Review 1.  MicroRNAs and genomic instability.

Authors:  Konrad Huppi; Natalia Volfovsky; Mark Mackiewicz; Timothy Runfola; Tamara L Jones; Scott E Martin; Robert Stephens; Natasha J Caplen
Journal:  Semin Cancer Biol       Date:  2006-10-26       Impact factor: 15.707

2.  The myeloid features of BXH2 leukemias may result from the lack of one copy of the repetitive sequence in the long terminal repeat viral enhancer.

Authors:  Liqun Huang; Motomi Osato; Masatoshi Yanagida; Namiko Yamashita; Yoshiaki Ito
Journal:  Int J Hematol       Date:  2007-02       Impact factor: 2.490

Review 3.  Mouse models of diseases of megakaryocyte and platelet homeostasis.

Authors:  Catherine L Carmichael; Warren S Alexander
Journal:  Mamm Genome       Date:  2011-06-11       Impact factor: 2.957

4.  Haploinsufficient tumor suppressor genes.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Adv Med Biol       Date:  2017 1st Quarter

Review 5.  Mouse models for core binding factor leukemia.

Authors:  D W L Chin; N Watanabe-Okochi; C Q Wang; V Tergaonkar; M Osato
Journal:  Leukemia       Date:  2015-07-13       Impact factor: 11.528

6.  Stem cell exhaustion due to Runx1 deficiency is prevented by Evi5 activation in leukemogenesis.

Authors:  Bindya Jacob; Motomi Osato; Namiko Yamashita; Chelsia Qiuxia Wang; Ichiro Taniuchi; Dan R Littman; Norio Asou; Yoshiaki Ito
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

Review 7.  A role for RUNX1 in hematopoiesis and myeloid leukemia.

Authors:  Motoshi Ichikawa; Akihide Yoshimi; Masahiro Nakagawa; Nahoko Nishimoto; Naoko Watanabe-Okochi; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

8.  Possible involvement of RasGRP4 in leukemogenesis.

Authors:  Naoko Watanabe-Okochi; Toshihiko Oki; Yukiko Komeno; Naoko Kato; Koichiro Yuji; Ryoichi Ono; Yuka Harada; Hironori Harada; Yasuhide Hayashi; Hideaki Nakajima; Tetsuya Nosaka; Jiro Kitaura; Toshio Kitamura
Journal:  Int J Hematol       Date:  2009-04-07       Impact factor: 2.490

9.  The zinc finger SET domain gene Prdm14 is overexpressed in lymphoblastic lymphomas with retroviral insertions at Evi32.

Authors:  E J Dettman; Monica J Justice
Journal:  PLoS One       Date:  2008-11-27       Impact factor: 3.240

10.  Orthologous microRNA genes are located in cancer-associated genomic regions in human and mouse.

Authors:  Igor V Makunin; Michael Pheasant; Cas Simons; John S Mattick
Journal:  PLoS One       Date:  2007-11-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.